Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Ab1003 Dose Level 2

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Completed1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05230459Phase 1/2Active Not Recruiting

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

NCT04349566Completed

Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases

Showing all 2 trials

Research Network

Common Treatments

  • Ab1003 Dose Level 21
  • Ab1003 Dose Level 11

Active Sponsors

  • Mads Peter Godtfeldt Stemmerik1
  • AskBio Inc1
  • Edgewise Therapeutics, Inc.1

Related Conditions

  • Limb Girdle Muscular Dystrophy1
  • Lgmd1
  • Fukutin Related Protein1
  • Lgmd21
  • Mcardle Disease1

Activity Timeline